NO20022333L - Ny anvendelse av antistoffer som vaksiner - Google Patents

Ny anvendelse av antistoffer som vaksiner

Info

Publication number
NO20022333L
NO20022333L NO20022333A NO20022333A NO20022333L NO 20022333 L NO20022333 L NO 20022333L NO 20022333 A NO20022333 A NO 20022333A NO 20022333 A NO20022333 A NO 20022333A NO 20022333 L NO20022333 L NO 20022333L
Authority
NO
Norway
Prior art keywords
vaccines
antibodies
new use
new
Prior art date
Application number
NO20022333A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022333D0 (no
Inventor
Hans Loibner
Helmut Eckert
Gottfried Himmler
Original Assignee
Igeneon Krebs Immuntherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs Immuntherapie filed Critical Igeneon Krebs Immuntherapie
Publication of NO20022333D0 publication Critical patent/NO20022333D0/no
Publication of NO20022333L publication Critical patent/NO20022333L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20022333A 1999-11-16 2002-05-15 Ny anvendelse av antistoffer som vaksiner NO20022333L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0192799A AT409086B (de) 1999-11-16 1999-11-16 Neue verwendung von antikörpern als impfstoffe
PCT/EP2000/011306 WO2001035989A2 (fr) 1999-11-16 2000-11-15 Nouvelle utilisation d'anticorps en tant que vaccins

Publications (2)

Publication Number Publication Date
NO20022333D0 NO20022333D0 (no) 2002-05-15
NO20022333L true NO20022333L (no) 2002-06-03

Family

ID=3524036

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022333A NO20022333L (no) 1999-11-16 2002-05-15 Ny anvendelse av antistoffer som vaksiner

Country Status (24)

Country Link
EP (1) EP1229936B1 (fr)
JP (1) JP2003514028A (fr)
KR (1) KR20020060968A (fr)
CN (1) CN1390138A (fr)
AT (1) AT409086B (fr)
AU (1) AU780853B2 (fr)
BR (1) BR0015597A (fr)
CA (1) CA2391927A1 (fr)
CZ (1) CZ20021707A3 (fr)
DE (1) DE50006526D1 (fr)
DK (1) DK1229936T3 (fr)
EE (1) EE200200252A (fr)
ES (1) ES2218272T3 (fr)
HU (1) HUP0204216A2 (fr)
IL (1) IL149614A0 (fr)
IS (1) IS6381A (fr)
MX (1) MXPA02004942A (fr)
NO (1) NO20022333L (fr)
NZ (1) NZ518669A (fr)
PL (1) PL356770A1 (fr)
PT (1) PT1229936E (fr)
SK (1) SK6542002A3 (fr)
TR (1) TR200401267T4 (fr)
WO (1) WO2001035989A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017108A (en) * 1975-04-17 1977-04-12 Archibald Kenrick And Sons Limited Window stay
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
AT410172B (de) * 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT410637B (de) * 2001-06-01 2003-06-25 Igeneon Krebs Immuntherapie Verwendung von polyklonalen immunglobulinen
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
WO2007024825A2 (fr) * 2005-08-26 2007-03-01 Genway Biotech, Inc. Separation par immunoaffinite et compositions et procedes d'analyse
EP2044949A1 (fr) 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
US20180008702A1 (en) * 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002848A1 (fr) * 1983-01-28 1984-08-02 Centocor Inc Anticorps anti-idiotypiques aux recepteurs antigenes des cellules t
ES2015654A6 (es) * 1988-05-17 1990-09-01 Soldano Ferrone Un procedimiento para preparar anticuerpos anti-idiotipicos para antigeno asociado con melanoma, de alto peso molecular anti-humano.
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
IT1254315B (it) * 1992-03-27 1995-09-14 Mini Ricerca Scient Tecnolog Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf.
WO1994001133A1 (fr) * 1992-07-08 1994-01-20 Schering Corporation Utilisation de facteur de stimulation de colonie de granulocytes-macrophages (fsc-gm) comme adjuvant de vaccin
CA2209172C (fr) * 1994-12-28 2007-04-10 University Of Kentucky Anticorps 3h1 monoclonal anti-idiotype murin

Also Published As

Publication number Publication date
AT409086B (de) 2002-05-27
JP2003514028A (ja) 2003-04-15
PT1229936E (pt) 2004-09-30
EE200200252A (et) 2003-06-16
WO2001035989A2 (fr) 2001-05-25
KR20020060968A (ko) 2002-07-19
NO20022333D0 (no) 2002-05-15
CN1390138A (zh) 2003-01-08
IL149614A0 (en) 2002-11-10
IS6381A (is) 2002-05-14
AU780853B2 (en) 2005-04-21
DE50006526D1 (de) 2004-06-24
EP1229936A2 (fr) 2002-08-14
AU2357201A (en) 2001-05-30
ATA192799A (de) 2001-10-15
NZ518669A (en) 2003-08-29
TR200401267T4 (tr) 2004-07-21
ES2218272T3 (es) 2004-11-16
EP1229936B1 (fr) 2004-05-19
BR0015597A (pt) 2002-07-23
WO2001035989A3 (fr) 2001-10-04
HUP0204216A2 (en) 2003-04-28
CZ20021707A3 (cs) 2002-10-16
MXPA02004942A (es) 2003-10-14
SK6542002A3 (en) 2002-11-06
CA2391927A1 (fr) 2001-05-25
DK1229936T3 (da) 2004-08-30
PL356770A1 (en) 2004-07-12

Similar Documents

Publication Publication Date Title
PT1210113E (pt) Composicoes de vacinas de combinacao
FI20000677A0 (fi) Oksiimijohdannaiset ja niiden käyttö latentteina happoina
SE0001090L (sv) Oximderivat och deras användning som latenta syror
NO20014322D0 (no) Vaksine
CY2007029I1 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
ATE490327T1 (de) Impfstoffzusammensetzung
CY2011008I1 (el) Εμβολιο γριπης
NO20015855D0 (no) Ny anvendelse av forbindelser som antibakterielle midler
DE60217126D1 (de) Herstellung von aminopyrimidinverbindungen
ID30393A (id) Senyawa tienopirimidina, pembuatan dan penggunaannya
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20020763D0 (no) Vaksine
DE60019960D1 (de) Herstellung von isobutencopolymere
NO20022333D0 (no) Ny anvendelse av antistoffer som vaksiner
NO20042667L (no) Fremgangsmate for fremstilling av escitalopram
DK1216250T3 (da) Thienoisoxazolyl- og thienylpyrazolyl-phenoxy- substituerede propylderivater som D4-antagonister
NO20041968L (no) Anvendelse av cystationin
DE60142051D1 (de) Herstellung von perfluorolefinen
NO20025423D0 (no) FremgangsmÕte for fremstilling av Citalopram
NO20021730L (no) Ny formulering av mirtazapin
NO20030515L (no) Fremgangsmåte for fremstilling av dinapsolin
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
NO20033163L (no) Ny anvendelse av iloperidon
NO20023702L (no) Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
NO20021249L (no) Tienoisoksazolfenoksyusubstituerte etyl- og propylderivater anvendbare som D4antagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application